reduction of adrenodoxin promotes its dissociation from the reductase.Adrenodoxin is now shown to associate preferentially with cytochrome P-450,,, to which cholesterol is bound, to form an adrenodoxincytochrome P-450 *cholesterol ternary complex.T h e Kd for adrenodoxin binding to cholesterol-free cytochrome is 600 1 1 ~ compared with 30 nM for cholesterol-bound hemoprotein.To vary the binding of cholesterol to cytochrome, the cytochrome was reconstituted into liposomes of varying cholesterol/phospholipid ratios.In the absence of cholesterol, the preparation had a low spin optical spectrum; the fraction of hemoprotein in the high spin form was proportional to the cholesterol/ phospholipid ratio rather than to the total cholesterol concentration (calculated on the basis of the total aqueous volume).Adrenodoxin caused a further conversion to high spin when cholesterol was present in the membrane and a smaller conversion when cholesterol was absent; adrenodoxin-induced spin state changes occurred rapidly (<3 ms) when both hemoprotein and cholesterol were membrane-associated, suggesting that neither interaction of cholesterol nor of adrenodoxin with cytochrome P-450.,, is rate-limiting in the overall hydroxylation.The data indicate that cholesterol and adrenodoxin both bind preferentially to the same form of cytochrome P-450.,, and calculations show that the binding of either to cytochrome increases the binding of the other by a factor of -20.We suggest that this mechanism causes preferential interaction of adrenodoxin with cytochrome P-450 to which substrate is bound, and may function to prevent the hemoprotein from operating as a futile NADPH or adrenodoxin oxidase.Results are also consistent with previous findings (Seybert,
No takes yet. Share an insight, caveat, or question.
Lambeth et al. (1980) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: